| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
716 |
706 |
$249K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,057 |
957 |
$43K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
528 |
526 |
$39K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
525 |
524 |
$30K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
614 |
572 |
$18K |
| 87631 |
|
103 |
100 |
$6K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
630 |
607 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
249 |
225 |
$3K |
| 99000 |
|
864 |
821 |
$3K |
| 81002 |
|
323 |
303 |
$647.86 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
15 |
15 |
$529.95 |
| 94664 |
|
54 |
51 |
$434.08 |
| 87807 |
|
20 |
20 |
$160.63 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
17 |
17 |
$128.35 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
116 |
111 |
$3.51 |